spyre therapeutics inc - SYRE
SYRE
Close Chg Chg %
103.86 0.92 0.88%
Open Market
104.78
+0.92 (0.88%)
Volume: 19.29K
Last Updated:
Nov 9, 2026, 9:34 AM EDT
Company Overview: spyre therapeutics inc - SYRE
SYRE Key Data
| Open $105.59 | Day Range 104.41 - 106.08 |
| 52 Week Range 21.15 - 110.18 | Market Cap $9.14B |
| Shares Outstanding 92.29M | Public Float 85.27M |
| Beta 3.25 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$3.08 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.19M |
SYRE Performance
| 1 Week | 0.00% | ||
| 1 Month | 21.20% | ||
| 3 Months | -1.00% | ||
| 1 Year | 361.19% | ||
| 5 Years | -40.99% |
SYRE Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
17
Full Ratings ➔
About spyre therapeutics inc - SYRE
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.
SYRE At a Glance
Spyre Therapeutics, Inc.
Building 23
Waltham, Massachusetts 02453
| Phone | 1-617-651-5940 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -126,541,000.00 | |
| Sector | Health Technology | Employees | 102 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
SYRE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 4.579 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -6.822 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
SYRE Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,240,598.039 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
SYRE Liquidity
| Current Ratio | 13.253 |
| Quick Ratio | 13.253 |
| Cash Ratio | 12.891 |
SYRE Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -18.256 |
| Return on Equity | -20.525 |
| Return on Total Capital | -17.692 |
| Return on Invested Capital | -20.525 |
SYRE Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Spyre Therapeutics Inc - SYRE
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | 2.33M | 886.00K | - |
Sales Growth
| - | -87.57% | -61.96% | -100.00% | |
Cost of Goods Sold (COGS) incl D&A
| - | - | 1.96M | 964.00K | - |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| - | - | 1.96M | 964.00K | - |
Depreciation
| - | - | 1.96M | 964.00K | - |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | -1.85% | -50.92% | -100.00% | |
Gross Income
| - | - | 365.00K | (78.00K) | - |
Gross Income Growth
| - | -97.82% | -121.37% | +100.00% | |
Gross Profit Margin
| - | - | +15.67% | -8.80% | - |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 85.15M | 117.53M | 208.57M | 219.56M | |
Research & Development
| 58.58M | 84.05M | 162.79M | 171.65M | |
Other SG&A
| 26.57M | 33.49M | 45.78M | 47.91M | |
SGA Growth
| +3.35% | +38.04% | +77.45% | +5.27% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | 224.67M | - |
EBIT after Unusual Expense
| (84.78M) | (342.28M) | (208.57M) | (219.56M) | |
Non Operating Income/Expense
| 830.00K | 3.47M | 599.00K | 64.34M | |
Non-Operating Interest Income
| 837.00K | 6.15M | 21.31M | 24.89M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (83.95M) | (338.82M) | (207.97M) | (155.22M) | |
Pretax Income Growth
| -27.86% | -303.59% | +38.62% | +25.36% | |
Pretax Margin
| - | - | -3,604.59% | -38,241.08% | - |
Income Tax
| (136.00K) | (26.00K) | 51.00K | (15.00K) | |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | 243.91M | 58.46M | 28.66M | |
Consolidated Net Income
| (83.81M) | (94.88M) | (149.56M) | (126.54M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (83.81M) | (94.88M) | (149.56M) | (126.54M) | |
Net Income Growth
| -27.38% | -13.21% | -57.62% | +15.39% | |
Net Margin Growth
| - | - | -3,598.75% | -10,709.14% | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (83.81M) | (94.88M) | (149.56M) | (126.54M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (83.81M) | (94.88M) | (149.56M) | (126.54M) | |
EPS (Basic)
| -24.8618 | -13.757 | -3.1801 | -1.9755 | |
EPS (Basic) Growth
| +0.64% | +44.67% | +76.88% | +37.88% | |
Basic Shares Outstanding
| 3.37M | 6.90M | 47.03M | 64.06M | |
EPS (Diluted)
| -24.8618 | -13.757 | -3.1801 | -1.9755 | |
EPS (Diluted) Growth
| +0.64% | +44.67% | +76.88% | +37.88% | |
Diluted Shares Outstanding
| 3.37M | 6.90M | 47.03M | 64.06M | |
EBITDA
| (82.82M) | (116.65M) | (208.57M) | (219.56M) | |
EBITDA Growth
| -30.12% | -40.85% | -78.80% | -5.27% | |
EBITDA Margin
| - | - | -3,555.90% | -13,165.69% | - |
Snapshot
| Average Recommendation | BUY | Average Target Price | 122.733 | |
| Number of Ratings | 17 | Current Quarters Estimate | -1.016 | |
| FY Report Date | 12 / 2026 | Current Year's Estimate | -3.109 | |
| Last Quarter’s Earnings | -0.94 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.98 | Next Fiscal Year Estimate | -3.827 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 15 | 7 | 15 | 15 |
| Mean Estimate | -1.02 | -0.97 | -3.11 | -3.83 |
| High Estimates | -0.50 | -0.67 | -2.53 | -2.36 |
| Low Estimate | -1.91 | -1.12 | -3.95 | -4.65 |
| Coefficient of Variance | -31.22 | -15.10 | -11.74 | -14.45 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 15 | 15 | 13 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Spyre Therapeutics Inc - SYRE
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Spyre Therapeutics Inc - SYRE
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Oct 5, 2026 | Heidy Abreu King-Jones See Remarks | 5,445 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $92.7 per share | 504,751.50 |
| Oct 5, 2026 | Scott L. Burrows Chief Financial Officer | 312,357 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Oct 5, 2026 | Scott L. Burrows Chief Financial Officer | 79,991 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $92.95 per share | 7,435,163.45 |
| Oct 5, 2026 | Scott L. Burrows Chief Financial Officer | 83,062 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $91.92 per share | 7,635,059.04 |
| Oct 5, 2026 | Scott L. Burrows Chief Financial Officer | 85,162 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $90.27 per share | 7,687,573.74 |
| Oct 5, 2026 | Scott L. Burrows Chief Financial Officer | 86,662 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $89.07 per share | 7,718,984.34 |
| Oct 5, 2026 | Scott L. Burrows Chief Financial Officer | 87,262 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $14.5 per share | 1,265,299.00 |
| Oct 5, 2026 | Scott L. Burrows Chief Financial Officer | 79,762 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $89.89 per share | 7,169,806.18 |
| Oct 5, 2026 | Scott L. Burrows Chief Financial Officer | 97,262 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $14.5 per share | 1,410,299.00 |
| Oct 5, 2026 | Heidy Abreu King-Jones See Remarks | 482,478 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Oct 5, 2026 | Heidy Abreu King-Jones See Remarks | 2,845 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $93.46 per share | 265,893.70 |
| Oct 5, 2026 | Cameron Turtle Chief Executive Officer; Director | 551,940 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $89.14 per share | 49,199,931.60 |
| Oct 5, 2026 | Heidy Abreu King-Jones See Remarks | 7,545 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $91.35 per share | 689,235.75 |
| Oct 5, 2026 | Heidy Abreu King-Jones See Remarks | 14,773 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $90.35 per share | 1,334,740.55 |
| Oct 5, 2026 | Heidy Abreu King-Jones See Remarks | 31,378 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $89.24 per share | 2,800,172.72 |
| Oct 5, 2026 | Heidy Abreu King-Jones See Remarks | 31,778 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $14.5 per share | 460,781.00 |
| Oct 5, 2026 | Cameron Turtle Chief Executive Officer; Director | 537,540 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $93.91 per share | 50,480,381.40 |
| Oct 5, 2026 | Cameron Turtle Chief Executive Officer; Director | 537,640 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $93.37 per share | 50,199,446.80 |
| Oct 5, 2026 | Cameron Turtle Chief Executive Officer; Director | 542,630 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $92.31 per share | 50,090,175.30 |
| Oct 5, 2026 | Cameron Turtle Chief Executive Officer; Director | 546,619 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $91.49 per share | 50,010,172.31 |